Komiyama A, Arai H, Kijima M, Hirayama K
Department of Neurology, Urafune Hospital of Yokohama City University, Yokohama, Japan.
J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):214-7. doi: 10.1136/jnnp.68.2.214.
Three patients with generalised myasthenia gravis and three with ocular myasthenia gravis received two to five courses of high dose intravenous methylprednisolone because of the failure of standard immunomodulating therapies. Changes in myasthenic signs were assessed using a four step system for grading muscle weakness and fatiguability in 10 test items. Although a brief and modest amelioration was found from day 1 to day 2 after the initial infusion in two patients with generalised myasthenia gravis, all three experienced a prolonged phase of worsening followed by improvement before the next course. Conversely, for two of the patients with ocular myasthenia gravis, a transient but dramatic improvement of ptosis and ocular immobility was noted from 90 minutes to 5 hours after initiating the first infusion, followed by mild or no exacerbation. This 3 hour improvement may be related not only to possible differences in the neuromuscular junction, but also to corticosteroids unmasking the central adaptation for the peripheral ocular muscle weakness by increasing the acetylcholine release.
三名全身型重症肌无力患者和三名眼肌型重症肌无力患者因标准免疫调节疗法无效而接受了两到五个疗程的大剂量静脉注射甲基强的松龙治疗。使用一个四步系统对10个测试项目中的肌肉无力和疲劳性进行分级,以评估肌无力体征的变化。虽然在两名全身型重症肌无力患者首次输注后的第1天到第2天发现了短暂且轻微的改善,但所有三名患者在下一个疗程之前都经历了一个延长的病情恶化期,随后才有所改善。相反,对于两名眼肌型重症肌无力患者,在首次输注后90分钟到5小时观察到上睑下垂和眼球运动障碍出现短暂但显著的改善,随后病情轻微加重或未加重。这3小时的改善可能不仅与神经肌肉接头的可能差异有关,还与皮质类固醇通过增加乙酰胆碱释放来揭示中枢对周围眼肌无力的适应性有关。